A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; Revumenib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Acronyms SAVE

07 Dec 2024 According to a Syndax Pharmaceuticals media release, Result data from trial were presented at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024.
05 Nov 2024 According to a Syndax Pharmaceuticals media release, data from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting
05 Nov 2024 Results presented in the Syndax Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com